AEON Biopharma (NYSE American: AEON) faces added NYSE equity noncompliance risk
Rhea-AI Filing Summary
AEON Biopharma, Inc. reported that NYSE American sent an additional notice stating the company no longer meets an extra continued listing standard. The exchange requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years.
AEON instead reported a stockholders’ deficit of approximately $55 million as of December 31, 2025, along with losses in three of its four most recent fiscal years. The company is already operating under a previously accepted plan to regain compliance by August 3, 2026.
The new notice does not immediately affect trading of AEON’s Class A common stock, which will continue to list on NYSE American with a “.BC” below‑compliance indicator and inclusion on the noncompliant issuers list. If AEON fails to regain compliance by August 3, 2026, NYSE American may begin delisting proceedings, which AEON would have the right to appeal.
Positive
- None.
Negative
- Heightened delisting risk and deep equity deficit: NYSE American now deems AEON noncompliant with an additional equity standard, based on a stockholders’ deficit of about $55 million as of December 31, 2025, and losses in three of four recent years, increasing listing uncertainty if compliance is not restored by August 3, 2026.
Insights
AEON faces intensified NYSE American noncompliance risk, with a large equity deficit and delisting overhang.
AEON Biopharma now fails a second NYSE American equity standard. Section 1003(a)(ii) requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years, but AEON reported a stockholders’ deficit of about $55 million as of December 31, 2025.
The company was already operating under a NYSE American‑approved plan to regain compliance with Section 1003(a)(i) by August 3, 2026. The exchange has kept that Plan Period in place, and AEON’s shares continue to trade under the “AEON” symbol with a “.BC” indicator and appearance on the noncompliant issuers list.
If AEON does not restore compliance with Sections 1003(a)(i) and 1003(a)(ii) by August 3, 2026, NYSE American may initiate delisting proceedings, though AEON would be able to appeal. The company states that the notice does not affect current business operations or SEC reporting, so the immediate effect is reputational and listing‑status risk rather than operational disruption.
8-K Event Classification
Key Figures
Key Terms
continued listing standards regulatory
stockholders’ deficit financial
Plan Period regulatory
noncompliant issuers list regulatory
forward-looking statements regulatory
biosimilar medical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol | | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On March 31, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) received an additional written notice of non-compliance (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires stockholders’ equity of $4.0 million or more if a listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ deficit of approximately $55 million as of December 31, 2025 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years, as reflected in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 30, 2026.
As disclosed on a Form 8-K filed with the SEC on February 7, 2025, the Company received a prior notice from NYSE American that it was not in compliance with Section 1003(a)(i) of the Company Guide (the “Original Notice”), which requires stockholders’ equity of $2.0 million or more if a listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. Pursuant to the Original Notice, the Company submitted a plan to regain compliance with the continued listing standards of the Company Guide by August 3, 2026 (the “Plan”). In April 2025, the Plan was accepted by NYSE American and granted the Company until August 3, 2026 (the “Plan Period”) to regain compliance. The Company has been subject to periodic reviews by NYSE American and has been making progress consistent with the Plan.
The Notice is related to the Company’s previously disclosed compliance status following its year-end results and does not have immediate effect on the listing of the Company’s Class A Common Stock on NYSE American or the Plan Period. The Company’s Class A Common Stock will continue to be listed and traded on NYSE American during the Plan Period, subject to compliance with other applicable listing standards, and will continue to trade with a “.BC” indicator to denote that the Company is below compliance. The Company will also continue to be included in the NYSE American list of noncompliant issuers.
The Company intends to continue to execute the Plan to regain compliance with Sections 1003(a)(i) and 1003(a)(ii) by August 3, 2026. However, there can be no assurance that the Company will be able to regain compliance within the required timeframe. The Company has a right to appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.
The Company’s receipt of the Notice does not affect its business operations or its reporting obligations with the SEC.
The Company has issued a press release pursuant to Sections 402(g) and 1009(j) of the Company Guide disclosing receipt of the Notice, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s intent to regain compliance with the Company Guide and the Plan. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to those factors discussed in under the section entitled “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 30, 2026, as any such factors may be updated from time to time in the Company’s other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Company’s investor relations site at investors.aeonbiopharma.com. Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | ||||||||
99.1 | Press Release, dated April 3, 2026. | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AEON Biopharma, Inc. | ||
Date: April 3, 2026 | By: | /s/ Robert Bancroft |
Robert Bancroft | ||
President and Chief Executive Officer | ||
Exhibit 99.1
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
IRVINE, Calif., April 3, 2026 – AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the “Company Guide”).
As previously disclosed, on February 3, 2025, the Company received a notice (the “Original Notice”) that it was not in compliance with Section 1003(a)(i) of the Company Guide, which requires stockholders’ equity of at least $2.0 million if a listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. On April 22, 2025, NYSE American accepted the Company’s plan (the “Plan”) to regain compliance and granted the Company until August 3, 2026 (the “Plan Period”) to do so.
The current Notice indicates that the Company is now also not in compliance with Section 1003(a)(ii) of the Company Guide, which requires stockholders’ equity of at least $4.0 million if a listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. This determination is based on the Company’s reported stockholders’ deficit of approximately $55 million as of December 31, 2025, and losses from continuing operations and/or net losses in three of its four most recent fiscal years, as reported in the Company’s Annual Report on Form 10-K filed on March 30, 2026.
This Notice reflects an expected progression of the Company’s previously disclosed compliance status following its 2025 year-end results and does not have an immediate impact on the Company’s current listing, Plan Period, or Plan to regain compliance. The Company’s common stock will continue to trade on NYSE American under the symbol “AEON,” subject to the Company’s compliance with other listing standards. The Company’s ticker will continue to carry a “.BC” indicator to denote that it is below compliance, and the Company will remain listed on NYSE American’s noncompliant issuers list.
The Company remains subject to the terms of the Original Notice and continues to execute against the NYSE American approved Plan to regain compliance with NYSE American continued listing standards within the Plan Period. If the Company does not regain compliance by August 3, 2026, or does not make progress consistent with the Plan during the Plan Period, NYSE American may initiate delisting proceedings. The Company has a right to appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.
The Notice does not affect the Company’s business operations or its reporting obligations with the U.S. Securities and Exchange Commission.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOXÒ. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin
Exhibit 99.1
complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name JeuveauÒ. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of botulinum toxin products. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to continue to meet continued stock exchange listing standards; (v) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vi) the Company’s ability to comply with the Plan; and (vii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com
Source: AEON Biopharma